Features

Features

Pharma positions itself for 2026 amid an evolving US landscape

After President Donald Trump’s administration took office in early 2025, a series of policy changes have directly impacted the pharma…

Features

AI takes charge of data, but challenges linger

Features

APAC’s rising stars beyond China

Features

OCT DACH 2025: Geopolitics, trial equity and technology take centre stage

Features

Public sector R&D cuts could be the “silent economic killers” of US exceptionalism

Features

Multiple sclerosis: three trials to watch

Features

‘The time of the Einsteins is over’: Pharma urged to rethink trials for 2050

Features

Pharma R&D set to endure despite rising MFN costs

Features

Europe’s path to maintaining clinical trial hotbed of innovation

Features

OS endpoint focus will realign industry to “ultimate goal”

Annabel Kartal Allen

Features

Trials to watch: Three major catalysts in Alzheimer’s disease

News

What does the EU Data Act mean for businesses?

Features

From humble to global: China’s biotechs navigate the demands of international trials

Catherine Longworth

Features

Podcast: key trials and trends from ESC Congress 2025

Features

NSCLC: three trials to keep an eye on

Annabel Kartal Allen

Features

Podcast: Alternative testing models to shape toxicology “with time”

Annabel Kartal Allen

Features

China takes lead in CGT trials amid Western funding challenges

Features

Uncertainty remains over FDA block on China engineering of US cells

Features

Are concomitant medications complicating your clinical trial?

Features

Ukraine’s clinical trial surge amid war: a quiet comeback story

Features

Protocol flexibility and navigating the US geopolitical landscape in oncology clinical trials

Features

Accurate data interpretation key to expanding RWE in trials

Features

Adapting to funding and operational hurdles in today’s clinical trials landscape

Irena Maragkou and Frankie Fattorini

Features

EHDS regulation will depend on strong patient confidence

Features

Developing resilient strategies to overcome challenges in clinical research in Europe

Robert Barrie and Irena Maragkou

Features

Policy changes and digital strategies guide oncology research

Awards

Introducing the Clinical Trials Arena Excellence Awards 2025

Features

Psychedelic drug developers redesign trials to avoid Lykos faux pas

Features

Patient-centric trials: progress but gaps remain

Features

Power of collaboration more pertinent than ever says pharma experts

Features

Pharma’s AI prospects get nudged into the future with EU’s AI act

Features

Are regulators keeping pace with AI adoption in clinical trials?

Features

How can pharma manage rising trial costs?

Features

Can AI replace medical writers? Experts say not immediately

Frankie Fattorini

Features

WHO releases Lancet papers that delve further into clinical trial guidance

Features

Sigrid’s Carb Fence tech targets patients being left behind by GLP1s

Joshua Silverwood

Features

Duchenne muscular dystrophy: Five trials to watch

Joshua Silverwood

Features

Rising Sirturo resistance highlights urgent need for new TB therapies

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close